amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)
amivantamab and hyaluronidase-lpuj is an FDA-licensed reference biologic from Janssen Biotech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2026
Reference approved
Reference product
Rybrevant Faspro amivantamab and hyaluronidase-lpuj
Janssen Biotech, Inc.
- Approved
- Feb 13, 2026
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for amivantamab and hyaluronidase-lpuj, in chronological order.
Reference approval
Approval date of the reference amivantamab and hyaluronidase-lpuj product.
4 mo ago
Frequently asked questions
Are there biosimilars approved for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)?
No 351(k) biosimilars or interchangeable biosimilars referencing amivantamab and hyaluronidase-lpuj are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.